Commerzbank Aktiengesellschaft FI Has $500,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Commerzbank Aktiengesellschaft FI increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 19.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 3,081 shares of the company’s stock after purchasing an additional 491 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Zoetis were worth $500,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Bahl & Gaynor Inc. boosted its position in shares of Zoetis by 2.9% during the 4th quarter. Bahl & Gaynor Inc. now owns 162,808 shares of the company’s stock worth $26,526,000 after acquiring an additional 4,522 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Zoetis by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,394,355 shares of the company’s stock worth $553,042,000 after acquiring an additional 39,448 shares in the last quarter. Schechter Investment Advisors LLC boosted its position in shares of Zoetis by 14.2% during the 4th quarter. Schechter Investment Advisors LLC now owns 13,186 shares of the company’s stock worth $2,148,000 after acquiring an additional 1,641 shares in the last quarter. Meridian Wealth Management LLC boosted its position in shares of Zoetis by 10.7% during the 4th quarter. Meridian Wealth Management LLC now owns 1,645 shares of the company’s stock worth $268,000 after acquiring an additional 159 shares in the last quarter. Finally, Mission Wealth Management LP boosted its position in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after acquiring an additional 59 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, StockNews.com lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $215.90.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $166.96 on Thursday. The firm has a market cap of $74.76 billion, a PE ratio of 30.52, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The firm’s fifty day moving average is $166.57 and its 200-day moving average is $176.99. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.